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Editorial
Nodding syndrome—we can now prevent it
On Monday December 21, 2015, an information session was
organized by the Ugandan Health minister Dr Elioda Tumwesigye
in Pader district, northern Uganda, to explain the results of the
investigations performed in Uganda to identify the cause of
nodding syndrome (NS).1
NS was ﬁrst reported in Uganda in the districts of Kitgum, Pader,
and Lamwo in 2009. Retrospective studies would suggest cases as
early as 1997. By May 2014, a total of 3320 cases of NS had been
registered and treated, as well as 5185 cases of epilepsy in the
affected districts. NS is a form of atonic epilepsy.2 Patients with
NS present with episodes of uncontrollable nodding of the head
(the head drops forward), mental retardation, and stunted growth,
and often develop generalized convulsions.3 The Ugandan Health
minister informed the local population that NS was caused by
onchocerciasis, probably through an autoimmune response
triggered by an Onchocerca volvulus infection, the nematode
causing river blindness.1
Indeed many studies have now conﬁrmed the association
between NS, epilepsy, and onchocerciasis.3–5 An autoimmune
encephalitis caused by antibodies cross-reacting with O. volvulus
or Wolbachia (a bacterial symbiont of O. volvulus) could be an
explanation for this association. Johnson et al. reported that 11 (58%)
of 19 patients with NS presented leiomodin 1 antibodies compared
to ﬁve (26%) of 19 matched controls (matched odds ratio 7,
conﬁdence interval 0.9–11.1).6 These antibodies were found to be
neurotoxic in vitro and to cross-react with O. volvulus tropomyosin.
However, because leiomodin 1 is an intracellular protein, it is
possible that these antibodies are not causing the epilepsy but are
rather the consequence of repeated seizures damaging the brain.6 In
a small pilot study in Tanzania, antibodies against N-methyl-D-
aspartate receptor and voltage gated potassium channel complex
(VGKC) (LG1 and Caspr2) were not detected in patients with NS.7 In
contrast, in Uganda, antibodies to the VGKC proteins were more
often observed in patients with NS (15/31, 48.3%) than in controls
(1/11, 9.1%) (R. Idro et al., unpublished). No patient or control subject
had antibodies to the intracellular glutamic acid decarboxylase,
which is also associated with complex epilepsy.
Despite the fact that O. volvulus DNA has not yet been detected
in the cerebrospinal ﬂuid (CSF) of patients with NS,8,9 it is still
possible that microﬁlariae occasionally penetrate the brain,
particularly in highly infected individuals. In 1976 Duke et al.
noted the presence of small numbers of O. volvulus microﬁlariae in
the CSF (<2 mf/ml) in ﬁve of eight untreated heavily infected
(>100 mf/mg skin) onchocerciasis patients; furthermore, the
numbers of O. volvulus microﬁlariae in the CSF increased to 8–31
mf/ml during diethylcarbamazine treatment in 10 of 11 heavily
infected patients presenting with an ocular form of onchocercia-
sis.10 Patients with O. volvulus infection receiving diethylcarbam-
azine have also been reported to develop optic atrophy, probably
because of a Mazzotti reaction caused by the death of microﬁlariae
present in the optic nerve.11 O. volvulus microﬁlariae have been
detected in the optic nerve and optic nerve sheets,12 but so far not
in the brain. Recently, functional lymphatic vessels lining the dural
sinuses were discovered;13 could these vessels be an entry point
for microﬁlariae?
Brain samples from NS patients who died in Uganda were ﬂown
to the US Centers for Disease Control and Prevention in the USA for
analysis. A preliminary autopsy report showed that three of them
had multiple polarizable deposits in the brain.1 However, it
remains unclear whether these lesions were artefacts (myelin
altered by ﬁxation) or real brain lesions. A new post-mortem study
that includes controls and with appropriate processing of brain
tissue shortly after the death of the patient is needed to elucidate
the pathophysiological mechanism of NS and onchocerciasis-
associated epilepsy.
Prior to the NS outbreak in Uganda, only one post-mortem
examination had been performed on a child who had died of a
condition with similar clinical features as observed during an NS
epidemic—Nakalanga syndrome. During examination of the child’s
brain, histological changes were observed in the adenohypophysis,
but no deep-seated microﬁlariae.14
Nakalanga syndrome was ﬁrst described in 1950 among a
population that had migrated to the Mabira Forest, close to the city of
Jinja, on the east bank of the Nile in Uganda.15,16 Nakalanga
syndrome is characterized by extreme growth retardation and the
absence of external signs of sexual development; it is often but not
always associated with epilepsy.15,16 Nakalanga features were later
also reported from other onchocerciasis endemic foci, such as in
West Uganda,17 Burundi,18 and Ethiopia.19 In all these foci, the
syndrome disappeared once onchocerciasis control was established.
The hypothesis that blackﬂies are the cause of NS was proposed
in a publication in the International Journal of Infectious Diseases in
2014 and it was suggested that these blackﬂies could potentially
transmit a neurotropic virus.20 Today this hypothesis seems very
unlikely because the NS epidemic in northern Uganda stopped
following the mass distribution of ivermectin and the treatment of
the main rivers in the region, the Ashwa and the Pager, with
larvicides. A recent case–control study in Titule, Bas Ue´le´, an
onchocerciasis endemic region in the Democratic Republic of the
Congo (DRC), suggests that ivermectin has a protective effect on
individuals for developing epilepsy.21 In onchocerciasis hyper-
endemic regions, where ivermectin has not been introduced, the
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highest prevalence of NS and epilepsy is found among the 10–19
years age group.22 In a study in Kyarusozi sub-county in western
Uganda performed in 1991, 91% of epilepsy cases were below the
age of 19 years.22 In contrast, in the Imo river basin in Nigeria,
where ivermectin was distributed starting in 1994 but larviciding
was never implemented, 67% of the patients with epilepsy were
20–29 years old in 2002.23 This age shift in patients with epilepsy
after the introduction of ivermectin suggests that ivermectin may
reduce the incidence of epilepsy.
Therefore, the pathophysiological mechanism causing NS and
other forms of epilepsy in onchocerciasis endemic regions is
probably directly or indirectly related to the O. volvulus infection.
NS should be considered only the ‘ears of the hippo’, the hippo
being onchocerciasis-associated epilepsy.4 Indeed NS and other
forms of epilepsy appear clustered in speciﬁc villages and also
within households in onchocerciasis endemic regions.4,24 There-
fore they are likely to be caused by the same trigger: the O. volvulus
infection. NS, and also Nakalanga syndrome, should be considered
as different phenotypic presentations of onchocerciasis-associat-
ed epilepsy, or river epilepsy as proposed by Pion.25 Nakalanga
children are known to be very heavily infected with O. volvulus,
and the ﬁrst signs that a child will develop Nakalanga are already
evident during the child’s second or third year of life.15 These
children have become infected with O. volvulus at a very early age,
when their brains were still developing. Nakalanga children may
have been born from O. volvulus-infected mothers. Maternal
infection with O. volvulus has been shown to increase the risk of
children becoming infected with O. volvulus and developing
higher infection levels.26 An explanation for this may be that
parasite antigen exposure during prenatal or neonatal life may
depress the parasite-speciﬁc cellular immune responses in these
children.26–28 The in utero transmission of O. volvulus has also
been described.29 Other children, less exposed to O. volvulus and/
or exposed later in life, may develop only tonic–clonic epilepsy
with minimal or no mental retardation and no diminished growth
or sexual development.
The reason for the epidemic of NS/epilepsy in northern Uganda
and South Sudan is likely related to living conditions during the
war. In northern Uganda, beginning in 1996, hundreds of
thousands of people were put into internally displaced persons
camps, some of them very close to large rapid ﬂowing rivers
infested with O. volvulus-infected blackﬂies. In such camps, people
were living in households very close to each other. At that time
there was no mass drug administration of ivermectin in northern
Uganda in the Kitgum and Pader districts and this probably
resulted in an increasing number of O. volvulus infestations in
children with a weak immune system caused by malnutrition and
co-infections. These O. volvulus infestations were followed by an
epilepsy epidemic. The onchocerciasis hyper-endemicity in the
region was shown in 2009, when in a case–control study
microﬁlariae were observed in skin snips from 71% of patients
with epilepsy and 54% of controls.5
Before the war, herds of cattle in Kitgum and Pader were stolen by
the Karamajong (a tribe from north-east Uganda), and the remaining
cattle were eaten by rebels roaming the areas during the start of the
war (late 1980s). Blackﬂies of the species Simulium bovis normally
bite cows and transmit Onchocerca dukei (a cattle parasite closely
related to O. volvulus), but they also bite humans in this area,
particularly those herding cattle. Simulium damnosum s.l. is the main
vector transmitting O. volvulus, but this also bites cows and can
transmit Onchocerca ochengi (another closely related cattle parasite).
Humans are not known to develop any infection when exposed to
the bites of blackﬂies infected with either O. dukei or O. ochengi, but
they may develop antibodies against these cattle Onchocerca
nematodes that may protect them against O. volvulus-related
disease (or modulate the immune response in other ways).30 It is
possible that during the war, the disappearance of the cows resulted
in a decreased associated immunity against O. volvulus, which
together with malnutrition led to very severe O. volvulus infections
and the development of NS. O. volvulus and O. ochengi exhibit
extensive antigenic cross-reactivity, as evidenced by the serological
recognition of O. volvulus recombinant antigens by cattle infected
with O. ochengi,31 and can generate cross-protective responses both
experimentally32 and naturally.33 The protective effect of O. ochengi
antibodies against O. volvulus infection may explain why in Western
Equatoria Province of South Sudan, an onchocerciasis endemic area
with a high prevalence of NS, the Dinkas, who are cattle keepers,
were reported to be less likely to develop NS.34
Action is urgently needed because onchocerciasis-associated
epilepsy is catastrophic for entire villages. Many affected children
not only suffer from epilepsy, but also dementia and psychiatric
problems.35 Caretakers are left desperate and living in fear of
leaving their affected children alone, because some children simply
wander away, disappear, and die a lonely and tragic death mostly
due to burns or drowning. Many affected children drop out of
school and lack access to quality patient care. Since the start of
ivermectin distribution and larvicide treatment of rivers in
Uganda, the NS epidemic has declined dramatically. In contrast,
the situation continues to worsen in South Sudan because there is
very little distribution of ivermectin and no larviciding of rivers in
this country. Moreover, anti-epileptic treatment is generally not
available in the affected villages.
The burden of disease caused by onchocerciasis-associated
epilepsy remains to be determined. A high prevalence of epilepsy
has been observed in most onchocerciasis endemic regions with
low coverage of ivermectin.4,36,37 If 1% of the 36 million people
with O. volvulus infection (equivalent to the approximate excess
prevalence of epilepsy over non-endemic areas38) were to develop
epilepsy, the number of excess cases of epilepsy due to
onchocerciasis would be in the order of 360 000.4 This excess in
prevalence of epilepsy may be preventable by increasing the
coverage of ivermectin treatment. The fact that O. volvulus
increases the risk of epilepsy should be used as an additional
argument to strengthen onchocerciasis elimination plans and
motivate individuals to take the ivermectin at least annually.
Uganda has shown that providing symptomatic care, mainly
through timely consumption of anti-epilepsy drugs coupled with
proper nutrition, can achieve big improvements in patient
outcomes.39 In Uganda, many children even manage to go back
to school thanks to such treatment.
A lot of scientiﬁc progress has been made recently. We have
learned that improved onchocerciasis control will stop onchocer-
ciasis-associated epilepsy including NS. We have also learned from
rehabilitation centres in Uganda that NS is a manageable disease.40
The main challenge today is how to scale up and improve the
treatment of patients suffering from onchocerciasis-associated
epilepsy in all affected onchocerciasis regions of Africa. To deal
with this challenge we should learn from the experience gained
with the scaling up of HIV treatment in Africa. Similarly, for
onchocerciasis-associated epilepsy, we will need to apply advoca-
cy, ﬁghting ignorance and misconceptions, provide uninterrupted
free access to anti-epileptic treatment, including cheap and more
effective anti-epileptic drugs, and provide decentralized services to
diagnose and treat epilepsy early and to monitor treatment
adherence, a public health approach that includes task shifting,
training of primary and lower level health care workers, and
working with communities. The problem is that onchocerciasis-
associated epilepsy occurs in remote rural areas of Africa and
involves very poor populations, often in zones where the health
system is very weak and where there has been war or there is
instability. Moreover, this is not an illness that threatens the
industrialized world. Similar to the ﬁght against AIDS, to reach the
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goal of elimination of onchocerciasis-associated epilepsy will
require partnerships between scientists, communities and advo-
cacy groups, health care workers, ministries of health, non-
governmental organizations, the pharmaceutical industry, and
funding organizations.
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